Cargando…
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
INTRODUCTION: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis (PsO) and psoriatic arthritis (PsA), demonstrating a rapid onset of action and sustained responses wit...
Autores principales: | Spindeldreher, Sebastian, Maillère, Bernard, Correia, Evelyne, Tenon, Maxime, Karle, Anette, Jarvis, Philip, Kolbinger, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825325/ https://www.ncbi.nlm.nih.gov/pubmed/29392570 http://dx.doi.org/10.1007/s13555-018-0220-y |
Ejemplares similares
-
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018) -
T cell epitope mapping of secukinumab and ixekizumab in healthy donors
por: Spindeldreher, Sebastian, et al.
Publicado: (2020) -
Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
por: Karle, Anette, et al.
Publicado: (2016) -
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023) -
Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)